Skip to Content

Luxturna Approval History

  • FDA approved: Yes (First approved December 19th, 2017)
  • Brand name: Luxturna
  • Generic name: voretigene neparvovec
  • Dosage form: Intraocular Suspension for Subretinal Injection
  • Company: Spark Therapeutics, Inc.
  • Treatment for: Biallelic RPE65-Mediated Inherited Retinal Disease

Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).

Development History and FDA Approval Process for Luxturna

Dec 19, 2017Approval FDA Approves Luxturna (voretigene neparvovec-rzyl) Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss
Nov 10, 2017Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational Luxturna (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
Oct 19, 2017FDA Advisory Committee Unanimously Recommends Approval of Investigational Luxturna (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.